Date
of Report (Date of earliest event reported)
|
March 10,
2009
|
NEOPROBE CORPORATION
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
0-26520
|
31-1080091
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
425 Metro Place North, Suite 300, Columbus,
Ohio
|
43017
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code
|
(614)
793-7500
|
(Former
name or former address, if changed since last
report.)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
(b)
|
(c)
|
(d)
|
||||||||||||||||||||||||
(a)
|
Option
|
Restricted
|
All
Other
|
Total
|
||||||||||||||||||||||
Name and Principal Position
|
Year
|
Salary
|
Bonus
|
Awards
|
Stock Awards
|
Comp.
|
Compensation
|
|||||||||||||||||||
Anthony
K. Blair
|
2008
|
$ | 150,000 | $ | 15,700 | $ | 10,827 | $ | 8,975 | $ | 4,676 | $ | 190,178 | |||||||||||||
Vice
President,
|
2007
|
134,000 | 19,125 | 8,550 | - | 3,887 | 165,562 | |||||||||||||||||||
Manufacturing
Operations
|
||||||||||||||||||||||||||
David
C. Bupp
|
2008
|
$ | 325,000 | $ | 40,000 | $ | 43,875 | $ | 53,850 | $ | 7,208 | $ | 469,933 | |||||||||||||
President
and
|
2007
|
305,000 | 60,000 | 51,808 | - | 8,398 | 425,206 | |||||||||||||||||||
Chief
Executive Officer
|
||||||||||||||||||||||||||
Brent
L. Larson
|
2008
|
$ | 177,000 | $ | 15,000 | $ | 9,677 | $ | 8,975 | $ | 5,442 | $ | 216,094 | |||||||||||||
Vice
President, Finance
|
2007
|
170,000 | 19,125 | 10,184 | - | 4,896 | 204,205 | |||||||||||||||||||
and
Chief Financial Officer
|
(a)
|
Bonuses,
if any, have been disclosed for the year in which they were earned (i.e.,
the year to which the service
relates).
|
(b)
|
Amount
represents the dollar amount recognized for financial statement reporting
purposes in accordance with SFAS No. 123(R). Assumptions made
in the valuation of stock option awards are disclosed in Item 1(n) of the
Notes to the Consolidated Financial Statements filed with the Company’s
Registration Statement on Form S-1 (File No. 333-156810), dated January
20, 2009.
|
(c)
|
Amount
represents the dollar amount recognized for financial statement reporting
purposes in accordance with SFAS No. 123(R). Assumptions made
in the valuation of stock option awards are disclosed in Item 1(n) of the
Notes to the Consolidated Financial Statements filed with the Company’s
Registration Statement on Form S-1 (File No. 333-156810), dated January
20, 2009.
|
(d)
|
Amount
represents life insurance premiums paid during the fiscal year for the
benefit of the Named Executives and matching contributions under the
Neoprobe Corporation 401(k) Plan (the Plan). Eligible employees
may make voluntary contributions and we may, but are not obligated to,
make matching contributions based on 40 percent of the employee’s
contribution, up to five percent of the employee’s
salary. Employee contributions are invested in mutual funds
administered by an independent plan administrator. Company
contributions, if any, are made in the form of shares of common
stock. The Plan qualifies under section 401 of the Internal
Revenue Code, which provides that employee and company contributions and
income earned on contributions are not taxable to the employee until
withdrawn from the Plan, and that we may deduct our contributions when
made.
|
Exhibit
|
|
Number
|
Exhibit
Description
|
99.1
|
Neoprobe
Corporation press release dated March 10, 2009, entitled “Neoprobe
Announces 2008 Results with Record Medical Device
Sales.”
|
Neoprobe
Corporation
|
|||
Date: March
10, 2009
|
By:
|
/s/ Brent L. Larson
|
|
Brent
L. Larson, Vice President, Finance and Chief
Financial Officer
|
|||